



## **Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022**

November 2, 2022 at 7:00 AM EDT

DURHAM, N.C.--(BUSINESS WIRE)--Nov. 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based *ex vivo* allogeneic CAR T and *in vivo* gene editing therapies, today announced that it will publish financial results for the third quarter 2022 and provide a business update on November 8, 2022.

### **About Precision BioSciences, Inc.**

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221102005105/en/): <https://www.businesswire.com/news/home/20221102005105/en/>

### **Investor Contact:**

Mei Burris  
Director, Investor Relations and Finance  
[Mei.Burris@precisionbiosciences.com](mailto:Mei.Burris@precisionbiosciences.com)

### **Media Contact:**

Maurissa Messier  
Senior Director, Corporate Communications  
[Maurissa.Messier@precisionbiosciences.com](mailto:Maurissa.Messier@precisionbiosciences.com)

Source: Precision BioSciences, Inc.